Herman S. Weiss

Obstetrics and Gynecology

980 N Broadway
Massapequa, NY 11758

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

High-Content Screening and Computational Prediction Reveal Viral Genes That Suppress the Innate Immune Response.

High-Content Screening and Computational Prediction Reveal Viral Genes That Suppress the Innate Immune Response.

Journal: mSystems

Published: March 23, 2022

Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep.

Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep.

Journal: Drug delivery and translational research

Published: May 09, 2019

Pharmacokinetics and Tolerability of a Novel 17β-Estradiol and Progesterone Intravaginal Ring in Sheep.

Pharmacokinetics and Tolerability of a Novel 17β-Estradiol and Progesterone Intravaginal Ring in Sheep.

Journal: Journal of pharmaceutical sciences

Published: January 08, 2019

Screening and treatment for short cervical length in pregnancy: a physician survey in the United States.

Screening and treatment for short cervical length in pregnancy: a physician survey in the United States.

Journal: Archives of gynecology and obstetrics

Published: July 24, 2017

Effect of Extended 30 μg Ethinyl Estradiol with Continuous Low-Dose Ethinyl Estradiol and Cyclic 20 μg Ethinyl Estradiol Oral Contraception on Adolescent Bone Density: A Randomized Trial.

Effect of Extended 30 μg Ethinyl Estradiol with Continuous Low-Dose Ethinyl Estradiol and Cyclic 20 μg Ethinyl Estradiol Oral Contraception on Adolescent Bone Density: A Randomized Trial.

Journal: Journal of pediatric and adolescent gynecology

Published: July 21, 2015

Differences in reporting Pearl Indices in the United States and Europe: Focus on a 91-day extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.

Differences in reporting Pearl Indices in the United States and Europe: Focus on a 91-day extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.

Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Published: June 27, 2015

Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.

Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.

Journal: Contraception

Published: April 13, 2015

A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.

A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.

Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Published: December 20, 2014

Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.

Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.

Journal: Contraception

Published: June 16, 2014

Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women.

Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women.

Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Published: June 14, 2014

A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.

A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.

Journal: The Journal of urology

Published: November 07, 2013

Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.

Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.

Journal: Contraception

Published: August 26, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026